Exforge and Cabometyx drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Exforge (amlodipine besylate; valsartan) and Cabometyx (cabozantinib s-malate). Common drug interactions include arthralgia among males.
The phase IV clinical study analyzes what interactions people have when they take Exforge and Cabometyx. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.
What is Exforge?
Exforge has active ingredients of amlodipine besylate; valsartan. It is often used in high blood pressure. eHealthMe is studying from 13,350 Exforge users. Check the latest studies of Exforge.
What is Cabometyx?
Cabometyx has active ingredients of cabozantinib s-malate. eHealthMe is studying from 35,069 Cabometyx users. Check the latest studies of Cabometyx.
12 people who take Exforge and Cabometyx together, and have interactions are studied.
What are the common drug interactions of Exforge and Cabometyx, by gender? *:
female:
n/a
male:
- Arthralgia (joint pain)
- Ascites (accumulation of fluid in the abdominal cavity)
- Intraductal papillary mucinous neoplasm (tumour (neoplasm) that grows within the pancreatic ducts)
- Malaise (a feeling of general discomfort or uneasiness)
- Mental disorder (a psychological term for a mental or behavioural pattern or anomaly that causes distress or disability)
- Metastases to stomach (cancer spreads to stomach)
- Osteonecrosis of jaw (death of bone of jaw)
- Post procedural infection
- Venous thrombosis (blood clot (thrombus) that forms within a vein)
- Weight decreased
What are the common drug interactions of Exforge and Cabometyx, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
n/a
30-39:
n/a
40-49:
n/a
50-59:
n/a
60+:
- Skin disorder (skin disease)
- Drug ineffective
- Malignant neoplasm progression (cancer tumour came back)
- Meningorrhagia (bleeding from cerebral or spinal membranes)
What are the existing conditions these people have? *
- Renal Cell Carcinoma (a kidney cancer): 11 people, 91.67%
- Pain: 1 person, 8.33%
- Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 8.33%
- High Blood Pressure: 1 person, 8.33%
* Approximation only. Some reports may have incomplete information.
Do you take Exforge and Cabometyx?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Exforge and Cabometyx:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Exforge:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Cabometyx:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Exforge and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Cabometyx and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study uses data from the FDA. It is based on amlodipine besylate; valsartan and cabozantinib s-malate (the active ingredients of Exforge and Cabometyx, respectively), and Exforge and Cabometyx (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Nerve Injury and drugs of ingredients of palbociclib - now
- Could Dolutegravir cause Hair Loss? - now
- Lariam and Vertigo Aggravated for Women aged 60+ - 10 seconds ago
- Tracleer and Stomachache for Women aged 20-29 - 10 seconds ago
- Tracleer and Stomach Pain for Women aged 20-29 - 10 seconds ago
- Glucophage and Aspartate Aminotransferase Increased for Women aged 60+ - 11 seconds ago
- Tracleer and Pain - Abdomen for Women aged 20-29 - 11 seconds ago
- Tracleer and Belly Ache for Women aged 20-29 - 11 seconds ago
- Tracleer and Abdominal Cramps for Women aged 20-29 - 11 seconds ago
- Tracleer and Abdominal Pain for Women aged 20-29 - 12 seconds ago